Metokuriinijodidi en es it fr

Metokuriinijodidi Brand names, Metokuriinijodidi Analogs

Metokuriinijodidi Brand Names Mixture

  • No information avaliable

Metokuriinijodidi Chemical_Formula


Metokuriinijodidi RX_link

Metokuriinijodidi fda sheet

Metokuriinijodidi FDA

Metokuriinijodidi msds (material safety sheet)

Metokuriinijodidi Synthesis Reference

No information avaliable

Metokuriinijodidi Molecular Weight

469.955 g/mol

Metokuriinijodidi Melting Point

No information avaliable

Metokuriinijodidi H2O Solubility

Slightly soluble (43 mg/mL at pH 7.4)

Metokuriinijodidi State


Metokuriinijodidi LogP


Metokuriinijodidi Dosage Forms

Capsule (250mg); Tablet (500 mg); Powder for solution (200 mg/mL constituted)

Metokuriinijodidi Indication

For the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. CellCept should be used concomitantly with cyclosporine and corticosteroids.

Metokuriinijodidi Pharmacology

Mycophenolate mofetil is a prodrug of mycophenolic acid, an antibiotic substance derived from Penicillium stoloniferum. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase. Mycophenolic acid is important because of its selective effects on the immune system. It prevents the proliferation of T-cells, lymphocytes, and the formation of antibodies from B-cells. It also may inhibit recruitment of leukocytes to inflammatory sites.

Metokuriinijodidi Absorption

Rapidly absorbed following oral administration. In 12 healthy volunteers, the mean absolute bioavailability of oral mycophenolate mofetil relative to intravenous mycophenolate mofetil (based on MPA AUC) was 94%. Food (27 g fat, 650 calories) has no effect on the extent of absorption (MPA AUC) of mycophenolate mofetil.

Metokuriinijodidi side effects and Toxicity

Oral (LD50): Acute: 352 mg/kg [Rat], 1000 mg/kg [Mouse], and >6000 mg/kg [Rabbit]. Possible signs and symptoms of acute overdose could include the following: hematological abnormalities such as leukopenia and neutropenia, and gastrointestinal symptoms such as abdominal pain, diarrhea, nausea and vomiting, and dyspepsia.

Metokuriinijodidi Patient Information

No information avaliable

Metokuriinijodidi Organisms Affected

Humans and other mammals